Fish oil supplementation in F1 generation associated with naproxen, clenbuterol, and insulin administration reduce tumor growth and cachexia in Walker 256 tumor-bearing rats

Journal of Nutritional Biochemistry

Volumn 15, Issue 6, 2004, Pages 358-365

  Pinto Jr , João A ^a   Folador, Alessandra ^b   Bonato, Sandro J ^a   Aikawa, Júlia ^a   Yamazaki, Ricardo K ^a   Pizato, Natalia ^a   Facin, Mirela ^a   Grohs, Hans ^a   De Oliveira, Heloísa H P ^a   Naliwaiko, Katya ^a   Ferraz, Anete C ^a   Nishiyama, Anita ^a   Fernandez, Ricardo ^a   Curi, Rui ^b   Fernandes, Luiz C ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cancer cachexia; Clenbuterol; Fish oil; Insulin; Naproxen; Tumor growth; Walker 256 tumor

Indexed keywords

CHOLESTEROL; CLENBUTEROL; COCONUT OIL; DRUG METABOLITE; FISH OIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LACTIC ACID; NAPROXEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BLOOD LEVEL; CACHEXIA; CANCER INHIBITION; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFECT; DRUG POTENTIATION; EXPERIMENTAL MODEL; FEMALE; GLYCOGEN ANALYSIS; INOCULATION; LIVER; MALE; NONHUMAN; RAT; SKELETAL MUSCLE; TISSUE LEVEL; TUMOR GROWTH;

ANIMALS; BODY WEIGHT; CACHEXIA; CARCINOMA 256, WALKER; CLENBUTEROL; FEMALE; FISH OILS; INSULIN; NAPROXEN; RATS; RATS, WISTAR;

ANIMALIA; RATTUS NORVEGICUS;

EID: 2442498372     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2004.02.002     Document Type: Article

References (75)

1. Barber M.D., Ross J.A., Fearon K.C.H. Cancer cachexia. Surg Oncol. 8:1999;133-141
2. Costelli P., Tessitore L., Batetta B., Mulas M.F., Spano O., Pani P., Baccino F.M., Dessi S. Alterations of lipid and cholesterol metabolism in cachetic tumor-bearing rats are prevented by insulin. J Nutr. 129:1999;700-706
3. Tisdale M.J. Cancer cachexia metabolic alterations and clinical manifestations. Nutrition. 13:1997;1-7
4. Giacosa A., Frascio F., Sukkar S.G., Roncella S. Food intake and body composition in cancer cachexia. Nutrition. 12:1996;S20-23
5. Plata-Salamán C.R. Central nervous system mechanisms contributing to the cachexia-anorexia syndrome. Nutrition. 16:2000;1009-1012
6. Tisdale M.J. Metabolic abnormalities in cachexia and anorexia. Nutr. 16:2000;1013-1014
7. Tisdale M.J. Cancer anorexia and cachexia. Nutrition. 17:2001;438-442
8. Cahlin C., Körner A., Axelsson H., Wang W., Lundholm K., Svanberg E. Experimental cancer cachexia the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-γ, and tumor necrosis factor-α evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia. Cancer Res. 60:2000;5488-5493
9. Fernandes L.C., Machado U.F., Nogueira C.R., Carpinelli A.R., Curi R. Insulin scretion in Walker 256 tumor cachexia. Am J Physiol. 258:1990;E1033-1036
10. Tracey K.J., Lowry S.F., Fahei T.J. III, Albert J.D., Fong Y., Hesse D., Beutler B., Manogue K.R., Calvano S., Wei H., Cerami A., Shires G.T. Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet. 164:1987;415-422
11. 2 in the development of cancer cachexia. Med Sci Res. 15:1987;45-46
12. Simopoulos A.P. Essential fatty acids in health and chronic disease. Am J Clin Nutr. 70:1999;560S-569S
13. Rose D.P., Connoly J.M. Effects of fatty acids and eicosanoid synthesis inhibitors on the growth of two human prostate cancer cell lines. Prostate. 18:1991;243-254
14. Pandalai P.K., Pilat M.J., Yamazaki K., Naik H., Pienta K.J. The effects of omega-3 and omega-6 fatty acids on in vitro prostate cancer growth. Anticancer Res. 16:1996;815-820
15. Caygill C.P.J., Charlett A., Hill M.J. Fat, fish oil and cancer. Br J Cancer. 74:1996;159-164
16. Karmali R.A. Historical perspective and potential use of n-3 fatty acids in therapy of cancer cachexia. Nutr. 12:1996;S2-4
17. Sauer L.A., Dauchy R.T., Blask D.E. Mechanism for the antitumor and anticachetic effects of n-3 fatty acids. Cancer Res. 60:2000;5289-5295
18. Sauer L.A., Dauchy R.T., Blask D.E. Polyunsaturated fatty acids, melatonin, and cancer prevention. Biochem Pharmacol. 61:2001;1455-1462
19. Rose D.P., Connolly J.M. Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol Ther. 83:1999;217-244
20. Helton W.S., Espat N.J. Defining mechanisms of ω-3 fatty-acid activity. Nutrition. 17:2001;674-687
21. Endres S., Ghorbani R., Kelley V.E., Gerogilis K., Lonnemann G., van der Meer J.W.M., Cannon J.G., Rogers T.S., Klempner M.S., Weber P.C., Schaefer E.J., Wolff S.M., Dinarello C.A. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med. 320:1989;265-271
22. Meydani S.N., Lichtenstein A.H., Cornwall S., Meydani M., Goldin B.R., Rasmussen H., Dinarello C.A., Schaefer E.J. Immunological effects of National Cholesterol Education Panel Step-2 diets with and without fish-derived n-3 fatty acid enrichment. J Clin Invest. 92:1993;105-113
23. Wigmore S.J., Fearon K.C.H., Maingay J.P., Ross J.A. Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sci. 92:1997;215-221
24. Barber M.D., McMillan D.C., Preston T., Ross J.A., Fearon K.C.H. The metabolic response to feeding in weight-losing pancreatic cancer patients and its modulation by a fish oil-enriched nutritional supplement. Clin Sci. 98:2000;389-399
25. Fernandes L.C., Carpinelli A.R., Hell N.S., Curi R. Improvement of cancer cachexia and decrease of Walker 256 tumor growth by insulin administration in rats. Cancer Ther Contr. 1:1991;259-268
26. Moley J.F., Morisson S.D., Gorschboth C.M., Norton J.A. Body composition changes in rats with experimental cancer cachexia improvement with exogenous insulin. Cancer Res. 48:1988;2784-2787
27. Fernandes L.C., Marques da Costa M.M., Curi R. Metabolism of glucose, glutamine an pyruvate in lymphocytes from Walker 256 tumor-bearing rats. Braz J Med Biol Res. 27:1994;2539-2543
28. Costa Rosa L.F.B.P., Guimarães A.R.P., Safi D.A., Curi R., Williams J.F. Effect of various dietary fatty acids on enzyme activities of carbohydrate and glutamine metabolism and the metabolic responses of lymphocytes and macrophages during Walker-256 ascites cell tumor growth in rats. Biochem Mol Biol Int. 29:1993;33-45
29. Reeds P.J., Hay S.M., Dorward P.M., Palmer R.M. Stimulation of muscle growth by clenbuterol lack of effect on muscle protein biosynthesis. Br J Nutr. 56:1986;249-256
30. Yang Y.T., McElligot M.A. Multiple actions of β-adrenergic agonists on skeletal muscle and adipose tissue. Biochem J. 261:1989;1-10
31. Chance W.T., von Almen D., Benson D., Zhang F.-S., Fisher J.E. Clenbuterol decreases catabolism and increases hypermetabolism in burned rats. J Trauma. 31:1991;365-370
32. 2-agonist, retards atrophy in denervated muscles. Am J Physiol. 252:1987;E152-155
33. Chance W.T., Cao L., Zhang F.-S., Foley-Nelson T., Fisher J.E. Muscle-sparing effect of clenbuterol in tumor-bearing rats maitained on total parenteral nutrition. Surg Forum. 40:1989;411-413
34. Stallion A., Zhang F.-S., Chance W.T., Foley-Nelson T., Fisher J.E. Reversal of cancer cachexia in rats by cimaterol and supplementatal nutrition. Surgery. 110:1991;678-684
35. Stallion A., Foley-Nelson T., Chance W.T., Fisher J.E. Effects of increased B2-agonist dose in tumor-bearing animals. Nutr Cancer. 20:1993;251-260
36. Williams E.D., Karim S.M.M., Sandler M. Prostaglandin secretion by medullary carcinoma of the thyroid. A possible cause of the associated diarrhoea. Lancet. Jan 6;1(7532):1968;22-23
37. Lynch N.R., Salomon J.C. Tumor growth inhibition and potentiation of immunotherapy by indomethacin in mice. J Natl Cancer Inst. 62:1978;117-121
38. Homem-de-Bittencourt P.I. Jr, Pontieri V., Curi R., Lopes O.U. Effects of aspirin-like drugs on Walker 256 tumor growth and cachexia in rats. Braz J Med Biol Res. 22:1989;1039-1042
39. Fulton A.M. Inhibition of experimental metastasis with indomethacin role of macrophages and natural killer cells. Prostaglandins. 35:1988;413-425
40. Bennett B., Houghton J., Leaper D.J., Stamford I.F. Cancer growth, response to treatment and survival time in mice beneficial effect of the prostaglandin synthesis inhibition flurbiprofen. Prostaglandins. 17:1979;179-191
41. Trinder P. Determination of blood glucose an oxidase-peroxidase system with a non-carcinogenic chromogen. J Clin Pathol. 22:1969;158-161
42. Jung D.H., Biggs H.G., Moorehead W.R. Colorimetry of serum cholesterol with use of ferric acetate/uranyl acetate and ferrous sulfate/sulfuric acid reagents. Clin Chem. 21:1975;1526-1530
43. Young D.S. Effects of Preanalytical Variables on Clinical Laboratory Tests. 2nd ed:1997;AACC Press, Washington, DC
44. Henry R.J. Clinical Chemistry Principles and Technics. 1964;Harper & Row, New York. pp. 833-8
45. Engle P.C., Jones J.B. Causes an elimination of erratic blanks in enzymatic metabolite assay involving the use of NAD+ in alkaline hydrazine buffers improved conditions for the assay of L-glutamate, L-lactate, and other metabolites. Anal Biochem. 88:1978;475-484
46. Winterbourn C., Gutteridge J.M.C., Halliwell B. Doxorubicin-dependent lipid peroxidation at low partial pressure of oxygen. J Free Rad Biol Med. 1(1):1985;43-49
47. Miyasaka C.K., Mendonça J.R., Nishiyama A., Alves de Souza J.A., Pires de Melo M., Pithon-Curi T.C., Curi R. Comparative effects of fish oil given by gavage and fish oil-enriched diet on leukocytes. Life Sci. 69:2001;1739-1751
48. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:1976;248-254
49. Boyd N.F., Martin L.J., Noffel M., Lockwood G.A., Tritchler D.L. A meta analysis of studies of dietary fat and breast cancer risk. Br J Cancer. 68:1993;627-636
50. Caygill C.P.J., Charlett A., Hill M.J. Fat, fish oil and cancer. Br J Cancer. 74:1996;159-164
51. Aronson W.J., Glaspy J.A., Reddy S.T., Reese D., Heber D., Bagga D. Modulation of omega-3/omega-6 polyunsaturated ratios with dietary fish oils in men with prostate cancer. Urology. 58:2001;283-288
52. Collett E.D., Davidson L.A., Fan Y.-Y., Lupton J.R., Chapkin R.S. n-6 and n-3 Polyunsaturated fatty acids differentially modulate oncogenic Ras activation in colonocytes. Am J Physiol. 280:2001;C1066-1075
53. Cowing B.E., Saker K.E. Polyunsaturated fatty acids and epidermal growth factor receptor/mitogen-activated protein kinase signaling in mammary cancer. J Nutr. 131:2001;1125-1128
54. Dommels Y.E.M., Alink G.M., van Bladeren P.J., van Ommen B. Dietary n-6 and n-3 polyunsaturated fatty acids and colorectal carcinogenesis results from cultured colon cells, animal models and human studies. Environ Toxicol Pharmacol. 12:2002;233-244
55. Jiang W.G., Bryce R.P., Horrobin D.F. Essential fatty acids molecular and cellular basis of their anti-cancer action and clinical implications. Crit Rev Oncol Hematol. 3:1998;179-209
56. Begin M.E., Ells G., Das U.N., Horrobin D.F. Diferential killing of human carcinoma cells supplemented with n-3 and n-6 polyunsaturated fatty acids. J Natl Cancer Inst. 77:1986;1053-1062
57. Begin M.E., Ells G., Horrobin D.F. Polyunsaturated fatty acid-induced cytotoxicity against tumor cells and its relationship to lipid peroxidation. J Natl Cancer Inst. 80:1988;188-194
58. Begin M.E., Ells G. Effects of C18 fatty acids on breast carcinoma cells cultured in vitro. Anticancer Res. 7:1987;215-218
59. Subbaramaiah K., Zakin D., Weksler B.B., Dannenberg A.J. Inhibition of cyclooxygenase a novel approach in cancer prevention. Proc Soc Exp Biol Med. 216:1997;201-210
60. Chulada P.C., Thompson M.B., Mahler J.F., Doyle C.M., Gaul B.W., Lee C., Tiano H.F., Morham S.G., Amithies O., Langenbach R. Genetic disruption of Ptgs-1 as well as Ptgs-2, reduces intestinal tumorigenesis in Mim mice. Cancer Res. 60:2000;4705-4708
61. 2 production. J Oral Pathol Med. 30:2001;41-47
62. Gately S. The contribution of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev. 19:2000;19-27
63. Hilkens C.M., Snijderset A., Snijdewint F.G., Wierenga E.A., Kapsenberg M.L. Modulation of T-cell cytokine secretion by accessory-cell-derived products. Eur Respir J. 22:1996;90S-94S
64. Dempke W., Rie C., Grothey A., Schmoll H.J. Cyclooxygenase-2 a novel target for cancer chemotherapy. J Cancer Res Clin Oncol. 127:2001;411-417
65. Kirschenbaum A., Liu X.H., Yao S., Levine A.C. The role of cyclooxygenase-2 in prostate cancer. Urology. 58:2001;127-131
66. Gelin J., Anderson C., Lundholm K. Effects of indomethacin, cytokines, and cyclosporin A on tumor growth and the subsequent development of cancer cachexia. Cancer Res. 51:1991;880-885
67. Prescott S.M., Fitzpatrick F.A. Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta. 1470:2000;M69-78
68. Masferrer J.L., Leahy K.M., Koki A.T., Zweifel B.S., Settle S.L., Woerner B.M., Edwards A.D., Flickinger A.G., Moore R.J., Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60:2000;1306-1311
69. 2+ mobilization and cAMP in HT-29 human colon adenocarcinoma cells. Cancer Lett. 152:2000;217-222
70. 2-adrenergic agonists on muscle waste associated with tumour growth. Cancer Lett. 115:1997;113-118
71. Anderson P.T., Hefferich W.G., Parkhall L.C., Meakel R.A., Bergen W.G. Ractopamine increases total and myofibrilar protein synthesis in cultured rat myotubes. J Nutr. 120:1990;1677-1683
72. 2-adrenergic agonists on body composition and protein synthesis in the rat. Biosci Rep. 4:1984;83-91
73. Babit P., Booth F.W. Clenbuterol prevents or inhibits loss of specific mRNAs in atrophying rat skeletal muscle. Am J Physiol. 254:1988;C657-660
74. Benson D.W., Foley-Nelson T., Chance W.T., Zhang F.-S., James J.H., Fisher J.E. Decreased myofibrilar protein breakdown following treatment with clenbuterol. J Surg Res. 50:1991;1-5
75. Bartlett D.L., Charland S., Torosian M.H. Growth hormone, insulin, and somatostatin therapy of cancer cachexia. Cancer. 73:1994;1499-1504